#1
RANDOMIZED CONTROLLED TRIAL
R Timothy D Oliver, Graham M Mead, Gordon J S Rustin, Johnathan K Joffe, Nina Aass, Robert Coleman, Rhian Gabe, Philip Pollock, Sally P Stenning
PURPOSE: Initial results of a randomized trial comparing carboplatin with radiotherapy (RT) as adjuvant treatment for stage I seminoma found carboplatin had a noninferior relapse-free rate (RFR) and had reduced contralateral germ cell tumors (GCTs) in the short-term. Updated results with a median follow-up of 6.5 years are now reported. PATIENTS AND METHODS: Random assignment was between RT and one infusion of carboplatin dosed at 7 × (glomerular filtration rate + 25) on the basis of EDTA (n = 357) and 90% of this dose if determined on the basis of creatinine clearance (n = 202)...
March 10, 2011: Journal of Clinical Oncology
#2
REVIEW
Nasser H Hanna, Lawrence H Einhorn
New England Journal of Medicine, Volume 371, Issue 21, Page 2005-2016, November 2014.
November 20, 2014: New England Journal of Medicine
#3
REVIEW
Peter Albers, Walter Albrecht, Ferran Algaba, Carsten Bokemeyer, Gabriella Cohn-Cedermark, Karim Fizazi, Alan Horwich, Maria Pilar Laguna
CONTEXT: On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy, and follow-up of testicular cancer were established. OBJECTIVE: This article is a short version of the EAU testicular cancer guidelines and summarises the main conclusions from the guidelines on the management of testicular cancer. EVIDENCE ACQUISITION: Guidelines were compiled by a multidisciplinary guidelines working group. A systematic review was carried out using Medline and Embase, also taking Cochrane evidence and data from the European Germ Cell Cancer Consensus Group into consideration...
August 2011: European Urology
1